Gotham Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.43M | Sell |
18,986
-1,901
| -9% | -$842K | 0.02% | 813 |
|
|
2026
Q1 | $9.33M | Sell |
20,887
-624
| -3% | -$291K | 0.03% | 711 |
|
|
2025
Q4 | $9.75M | Sell |
21,511
-377
| -2% | -$162K | 0.04% | 643 |
|
|
2025
Q3 | $8.57M | Buy |
21,888
+532
| +2% | +$222K | 0.04% | 631 |
|
|
2025
Q2 | $9.51M | Sell |
21,356
-6,421
| -23% | -$2.96M | 0.06% | 494 |
|
|
2025
Q1 | $13.5M | Sell |
27,777
-2,334
| -8% | -$1.09M | 0.11% | 240 |
|
|
2024
Q4 | $12.1M | Buy |
30,111
+2,978
| +11% | +$1.38M | 0.12% | 232 |
|
|
2024
Q3 | $12.6M | Buy |
27,133
+2,422
| +10% | +$1.16M | 0.13% | 200 |
|
|
2024
Q2 | $11.6M | Buy |
24,711
+6,393
| +35% | +$2.77M | 0.15% | 133 |
|
|
2024
Q1 | $7.66M | Buy |
18,318
+1,225
| +7% | +$518K | 0.12% | 223 |
|
|
2023
Q4 | $6.95M | Buy |
17,093
+4,992
| +41% | +$1.84M | 0.13% | 180 |
|
|
2023
Q3 | $4.21M | Buy |
12,101
+648
| +6% | +$227K | 0.09% | 323 |
|
|
2023
Q2 | $4.03M | Sell |
11,453
-522
| -4% | -$176K | 0.09% | 312 |
|
|
2023
Q1 | $3.77M | Sell |
11,975
-13,765
| -53% | -$4.13M | 0.09% | 287 |
|
|
2022
Q4 | $7.43M | Sell |
25,740
-11,867
| -32% | -$3.62M | 0.21% | 87 |
|
|
2022
Q3 | $10.9M | Buy |
37,607
+8,791
| +31% | +$2.53M | 0.33% | 36 |
|
|
2022
Q2 | $8.12M | Buy |
28,816
+1,336
| +5% | +$358K | 0.26% | 77 |
|
|
2022
Q1 | $7.17M | Buy |
27,480
+4,725
| +21% | +$1.12M | 0.22% | 104 |
|
|
2021
Q4 | $5M | Buy |
22,755
+2,488
| +12% | +$484K | 0.16% | 151 |
|
|
2021
Q3 | $3.68M | Sell |
20,267
-16,038
| -44% | -$3.13M | 0.15% | 191 |
|
|
2021
Q2 | $7.32M | Buy |
+36,305
| New | +$7.59M | 0.31% | 73 |
|
|
2020
Q4 | – | Sell |
-1,527
| Closed | -$416K | – | 1104 |
|
|
2020
Q3 | $416K | Sell |
1,527
-8
| -0.5% | -$2.21K | 0.01% | 771 |
|
|
2020
Q2 | $446K | Sell |
1,535
-447
| -23% | -$121K | 0.01% | 768 |
|
|
2020
Q1 | $472K | Buy |
1,982
+845
| +74% | +$194K | 0.01% | 731 |
|
|
2019
Q4 | $249K | Sell |
1,137
-60,130
| -98% | -$12.2M | ﹤0.01% | 991 |
|
|
2019
Q3 | $10.4M | Buy |
61,267
+59,466
| +3,302% | +$10.5M | 0.18% | 146 |
|
|
2019
Q2 | $330K | Buy |
+1,801
| New | +$315K | 0.01% | 923 |
|
|
2018
Q2 | – | Sell |
-14,974
| Closed | -$2.44M | – | 1052 |
|
|
2018
Q1 | $2.44M | Sell |
14,974
-10
| -0.1% | -$1.63K | 0.03% | 471 |
|
|
2017
Q4 | $2.25M | Sell |
14,984
-95,516
| -86% | -$14.1M | 0.03% | 479 |
|
|
2017
Q3 | $16.8M | Sell |
110,500
-72,015
| -39% | -$10.8M | 0.25% | 118 |
|
|
2017
Q2 | $23.5M | Buy |
+182,515
| New | +$22M | 0.33% | 86 |
|
|
2016
Q4 | – | Sell |
-66,716
| Closed | -$5.82M | – | 1066 |
|
|
2016
Q3 | $5.82M | Sell |
66,716
-41,940
| -39% | -$3.96M | 0.08% | 334 |
|
|
2016
Q2 | $9.35M | Buy |
108,656
+103,610
| +2,053% | +$8.95M | 0.11% | 291 |
|
|
2016
Q1 | $401K | Sell |
5,046
-6,747
| -57% | -$610K | ﹤0.01% | 797 |
|
|
2015
Q4 | $1.48M | Buy |
+11,793
| New | +$1.42M | 0.02% | 546 |
|
Other funds holding VRTX
Gotham Asset Management's VRTX Position: Q2 2026 in Review
Gotham Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 9.1% in Q2 2026, selling an estimated $842K and leaving 18,986 shares worth $9.43M. The position accounts for 0.02% of the portfolio, ranked #813.
Gotham Asset Management first reported a position in VRTX in Q4 2015 and has held it in 35 quarters since. The position peaked at $23.5M in Q2 2017. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Gotham Asset Management held 18,986 shares of Vertex Pharmaceuticals worth $9.43M as of Q2 2026.
- Gotham Asset Management sold 1,901 Vertex Pharmaceuticals shares in Q2 2026, an estimated $842K.
- Vertex Pharmaceuticals made up 0.02% of Gotham Asset Management's portfolio in Q2 2026, its #813 holding.
- Gotham Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 35 quarters since.
- Gotham Asset Management's Vertex Pharmaceuticals position peaked at $23.5M in Q2 2017.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.